April 29, 2025Open Access

Uptake of and Disparities in Semaglutide and Tirzepatide Prescribing for Obesity in the US

Puntos clave

Los puntos clave no están disponibles para este artículo en este momento.

Resumen

This study uses data from the US nationwide electronic health record–based Epic Cosmos Dataset to examine prescriptions for semaglutide and tirzepatide, focusing on differences across race, ethnicity, social vulnerability, and urbanicity and assess the need for strategies to promote equitable access to these therapies.

Leer artículo completoexternamente

Me gusta

Guardar

Ver artículo completo

Cite This Study

Kim et al. (Tue,) studied this question.

synapsesocial.com/papers/69d71e0bcd480cb7e5f5083a https://doi.org/https://doi.org/10.1001/jama.2025.4735

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1Projected U.S. State-Level Prevalence of Adult Obesity and Severe Obesity2019 · 1,994 citations
2The Cosmos Collaborative: A Vendor-Facilitated Electronic Health Record Data Aggregation Platform2021 · 111 citations
3A Prescription for Achieving Equitable Access to Antiobesity Medications2023 · 40 citations
4Once-Weekly Semaglutide in Adults with Overweight or Obesity2021 · 4,507 citations
5Racial and Ethnic Disparities in Financial Barriers Among Overweight and Obese Adults Eligible for Semaglutide in the United States2022 · 46 citations

Me gusta

Guardar

Ver artículo completo